Evidence map›Paper›PMID 35396927›Full record

ReviewBirth defects research2022

Elucidating arrhythmogenic right ventricular cardiomyopathy with stem cells.

Kenneth R Laurita, Sunil K Vasireddi, Judith A Mackall

Open access · hybridAbstract readReview
In one paragraph

Review in Birth defects research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Kenneth R LauritaHeart and Vascular Research Center, MetroHealth Campus, Case Western Reserve University, Cleveland, Ohio, USA.
Sunil K VasireddiStanford Cardiovascular Institute, Department of Medicine, Stanford University, California, USA.
Judith A MackallHarrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Cardiovascular Institute of the South · USMetroHealth Medical Center · USUniversity Hospitals of Cleveland · US

Funding

Project 3 Genes to Omics-Informed Drugs: Drug Repositioning and Testing to Prevent AF ProgressionsP01HL158502 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Robert Alden Koeth · 2022 to 2026
$16.9M
Novel mechanisms and treatment of arrhythmia during resuscitationR01HL142754 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI KENNETH LAURITA, Lance D Wilson · 2020 to 2026
$3.4M
Optically guided catheter ablation of atrial fibrillationR01HL149369 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI HENDON, CHRISTINE P, LAURITA, KENNETH · 2019 to 2022
$2.8M
Fully optical high throughput screening platform for drug induced arrhythmiasR21HL123012 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI LAURITA, KENNETH · 2015 to 2016
$436k
NHLBI NIH HHS P01 HL158502NHLBI NIH HHS R01 HL142754NHLBI NIH HHS R01 HL149369NHLBI NIH HHS R21 HL123012
6 · The paper itself

Abstract

Human stems cells have sparked many novel strategies for treating heart disease and for elucidating their underlying mechanisms. For example, arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disorder that is associated with fatal arrhythmias often occurring in healthy young adults. Fibro-fatty infiltrate, a clinical hallmark, progresses with the disease and can develop across both ventricles. Pathogenic variants in genes have been identified, with most being responsible for encoding cardiac desmosome proteins that reside at myocyte boundaries that are critical for cell-to-cell coupling. Despite some understanding of the molecular signaling mechanisms associated with ARVC mutations, their relationship with arrhythmogenesis is complex and not well understood for a monogenetic disorder. This review article focuses on arrhythmia mechanisms in ARVC based on clinical and animal studies and their relationship with disease causing variants. We also discuss the ways in which stem cells can be leveraged to improve our understanding of the role cardiac myocytes, nonmyocytes, metabolic signals, and inflammatory mediators play in an early onset disease such as ARVC.

Indexed as

Arrhythmogenic Right Ventricular DysplasiaHeart VentriclesHumansMutationStem CellsarrhythmiaARVCcardiomyopathycytokinesdesmosomesgene mutationsstem cells

Identifiers

PMID35396927
PMCPMC9790231
OpenAlexW4223615349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.